Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
5(63%)
Results Posted
400%(4 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_2
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(1)
Terminated(2)

Detailed Status

Active, not recruiting3
Recruiting2
Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (50.0%)
Phase 24 (50.0%)

Trials by Status

recruiting225%
active_not_recruiting338%
completed113%
terminated225%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_2

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

NCT03026140
completedphase_1

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

NCT03400332
active_not_recruitingphase_2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
terminatedphase_1

BMS-986253 in Myelodysplastic Syndromes

NCT05148234
recruitingphase_1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03026140Phase 2

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Recruiting
NCT03400332Phase 1

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Completed
NCT02451982Phase 2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Active Not Recruiting
NCT05148234Phase 1

BMS-986253 in Myelodysplastic Syndromes

Terminated
NCT04572451Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Recruiting
NCT04347226Phase 2

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Terminated
NCT03689699Phase 1

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Active Not Recruiting
NCT04123379Phase 2

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8